This duality unravels multiple possible strategies to block ALK-dependent cancers: (1) inhibiting the ALK proliferative signaling with direct targeting of ALK or indirect targeting of downstream effectors; (2) activating the ALK proapoptotic signaling. The gene discussed is ALK; the disease is cancer.